NEA Management Company, LLC 13F holdings
NEA Management Company, LLC reported 26 positions with a total reported value of $1.6B as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: TRVI Trevi Therapeutics, Inc. (15.5%), MBX MBX Biosciences, Inc. (12.6%), GLUE Monte Rosa Therapeutics, Inc. (11.7%), CELC Celcuity Inc. (11.3%), SGP Spyglass Pharma, Inc. (10.4%). Against 2026-03-31 it opened 1 new position and exited 1. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when NEA Management Company, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 26 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| TRVI Trevi Therapeutics, Inc. | 13,222,228 | $246.6M | 15.5% |
| MBX MBX Biosciences, Inc. | 3,614,486 | $199.5M | 12.6% |
| GLUE Monte Rosa Therapeutics, Inc. | 7,692,298 | $186.2M | 11.7% |
| CELC Celcuity Inc. | 1,710,561 | $179.0M | 11.3% |
| SGP Spyglass Pharma, Inc. | 7,392,301 | $164.6M | 10.4% |
| SVRA Savara, Inc. | 24,471,264 | $150.7M | 9.5% |
| ZBIO Zenas BioPharma, Inc. | 4,023,219 | $102.1M | 6.4% |
| COUR Coursera, Inc. | 12,867,769 | $72.6M | 4.6% |
| AUPH Aurinia Pharmaceuticals, Inc. | 3,969,834 | $67.4M | 4.2% |
| CRSP CRISPR Therapeutics AG | 1,058,570 | $57.7M | 3.6% |
| ORIC ORIC Pharmaceuticals, Inc. | 4,118,621 | $44.6M | 2.8% |
| PHAT Phathom Pharmaceuticals, Inc. | 1,960,169 | $21.3M | 1.3% |
| KRRO Korro Bio, Inc. | 1,297,893 | $17.1M | 1.1% |
| XFOR X4 Pharmaceuticals, Inc. | 3,233,743 | $15.1M | 1.0% |
| CSBR Champions Oncology, Inc. | 1,713,720 | $10.6M | 0.7% |
| NKTX Nkarta, Inc. | 3,568,781 | $10.1M | 0.6% |
| CVRX CVRx, Inc. | 1,954,440 | $10.0M | 0.6% |
| BDTX Black Diamond Therapeutics, Inc. | 4,448,757 | $8.2M | 0.5% |
| KPTI Karyopharm Therapeutics Inc. | 576,780 | $5.6M | 0.4% |
| IVA Inventiva SA | 1,462,586 | $5.5M | 0.3% |
| LONA LeonaBio, Inc. | 464,398 | $4.3M | 0.3% |
| SNTI Senti Biosciences, Inc. | 3,775,615 | $4.2M | 0.3% |
| MRKR Marker Therapeutics, Inc. | 1,625,678 | $2.4M | 0.2% |
| OKUR OnKure Therapeutics, Inc. | 478,548 | $2.2M | 0.1% |
| IMA ImageneBio, Inc. | 50,005 | $295.0K | <0.1% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 1 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| KPTI Karyopharm Therapeutics Inc. | 576,780 | $5.6M | 0.4% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 1 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| Arcellx, Inc. | 3,045,262 | $349.7M | 19.9% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
No position was increased.
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| CELC Celcuity Inc. | 2,285,561 | 1,710,561 | -25.2% | $179.0M |
| CVRX CVRx, Inc. | 2,026,083 | 1,954,440 | -3.5% | $10.0M |
CIK 1512848 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
